🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

249 results for “ISTA” Clear

  1. A study to assess the safety and tolerability of next-generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) therapy. NEXTGEN-TIL-ACT

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Advanced epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors

    phase 1 other active

    1 trial

  2. A trial to learn how baxdrostat affects the heartbeat in healthy participants

    AstraZeneca AB

    Treatment-resistant hypertension, Primary aldosteronism, Uncontrolled hypertension

    phase 1 other active

    1 trial

  3. A trial to learn if AZD5335 alone and in combination with other treatments is safe and effective and how it moves through the body in people with solid tumors

    AstraZeneca AB

    Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive recurrent (PSR) ovarian cancer, Lung Adenocarcinoma, and endometrial cancer.

    phase 1 other active

    1 trial

  4. AV-101

    Vistagen Therapeutics

    Drug Drug Interaction

    phase 1 small molecule active

    1 trial

  5. An Open-Label, Phase 1b Study to Evaluate Safety, Tolerability and Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects with High Risk Essential Thrombocythaemia who are Resistant to or Intolerant of Hydroxycarbamide Therapy. The VECTRA Study

    Pharma Mar S.A.

    Thrombocythaemia

    phase 1 other active

    1 trial

  6. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Maribavir Tablets 200 mg, manufactured by Sun Pharmaceutical Industries Limited, India with LIVTENCITY® (Maribavir) Coated Tablets 200 mg, manufactured by: Catalent CTS, LLC Kansas City, United States of America, packed by: Takeda Ireland Limited Bray, Ireland, imported by: Takeda Pharma Ltda. Highway SP 340 S/N, km 133.5 Jaguariúna Administrative Building -SP CNPJ 60.397.775/

    Pharma Mar S.A.

    cytomegalovirus (CMV) infection and/or disease that is refractory (with or without resistance) to one or more prior therapies in adult patients who have undergone hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT)

    phase 1 other active

    1 trial

  7. BPX-601

    Regeneron UK Limited

    Metastatic Castration-resistant Prostate Cancer

    phase 1 mab terminated

    1 trial

  8. CTIM-76

    Context Therapeutics

    Platinum-resistant Ovarian Cancer

    phase 1 small molecule active

    1 trial

  9. Drug Product De-TIL-0255

    Nurix Therapeutics

    Platinum-resistant Ovarian Cancer

    phase 1 mab terminated

    1 trial

  10. ETC-159

    BRIGHT MINDS BIOSCIENCES INC.

    With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

    phase 1 small molecule active

    1 trial

  11. First-in-Human trial of DS9051b in participants with advanced solid tumors

    Daiichi Sankyo Europe GmbH

    Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metastatic Castration-resistant Prostate Cancer (CRPC)

    phase 1 other active

    1 trial

  12. First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)

    Bayer Schering Pharma AG

    Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expression

    phase 1 other active

    1 trial

  13. GB-5267 - IV only

    Generate Biomedicines

    Platinum-resistant Ovarian Cancer

    phase 1 mab active

    1 trial

  14. KVD824

    Kalvista Pharmaceuticals (Ireland) Limited

    Hereditary Angioedema

    phase 1 small molecule completed

    1 trial

  15. KVD824 Prototype 1 modified-release tablet

    Kalvista Pharmaceuticals (Ireland) Limited

    Hereditary Angioedema

    phase 1 small molecule completed

    1 trial

  16. Kristalose

    CUMBERLAND PHARMACEUTICALS INC

    Bowel Evacuant Prior to Colonoscopy

    phase 1 small molecule completed

    1 trial

  17. Locametz 25 micrograms kit for radiopharmaceutical preparation, -, Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Ophthalmics Europe

    Metastatic Castration-Resistant Prostate Cancer

    phase 1 small molecule active

    1 trial

  18. Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Castration Resistant Prostate Cancer (CRPC), Follicular Lymphoma (FL), Small Cell Lung Cancer (SCLC), Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 1 other active

    1 trial

  19. NKTR-214 (Cohort A)

    INOVIO PHARMACEUTICALS, INC.

    Metastatic Castration-resistant Prostate Cancer

    phase 1 small molecule completed

    1 trial

  20. NXP800 in subjects with Ovarian Cancer

    Pharma Mar S.A.

    Platinum-resistant, ARID1a-mutated ovarian, fallopian tube and primary peritoneal carcinoma

    phase 1 other active

    1 trial

  21. Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  22. Oxycodone Tamper Resistant

    China SXT Pharmaceuticals

    Chronic Pain

    phase 1 small molecule completed

    3 trials

  23. Pevonedistat

    Takeda Pharmaceuticals International AG

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  24. Pevonedistat

    Takeda Pharmaceuticals International AG

    Refractory Acute Lymphoblastic Leukemia

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources